Recipharm AB publishes its interim report for the second quarter 2020
April – June 2020 · Net sales amounted to SEK 3,081 million (1,867), an increase of 65% · EBITA increased by 83% and amounted to SEK 423 million (232) corresponding to an EBITA margin of 13.7% (12.4) · Strong profitable organic growth · Net positive COVID-19 impact on sales and earnings · Operating profit (EBIT) amounted to SEK 340 million (171) and was affected by non-recurring items of SEK +17 million (0) · Profit after tax amounted to SEK 300 million (94) corresponding to a net margin of 9.7% (5.0) · Earnings per share amounted to SEK 4.22 (1.38) before dilution